Plonmarlimab Shows High Response in Macrophage Activation Syndrome Clinical Trial
In a phase 2 trial, the GM-CSF-neutralizing antibody plonmarlimab achieved an 83.3 percent response rate in patients with refractory macrophage ...
In a phase 2 trial, the GM-CSF-neutralizing antibody plonmarlimab achieved an 83.3 percent response rate in patients with refractory macrophage ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.